Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric, Zhejiang Shibao, and Hongye Futures leading in premium rates, while CATL, China Merchants Bank, and Heng Rui Medicine are at the bottom of the list [1][2]. Premium Rate Summary - Northeast Electric (00042) has a premium rate of 847.37%, followed by Zhejiang Shibao (01057) at 428.73% and Hongye Futures (03678) at 283.73% [1]. - The lowest premium rates are observed in CATL (03750) at -11.13%, China Merchants Bank (03968) at -3.84%, and Heng Rui Medicine (01276) at 3.17% [1]. Deviation Value Summary - The highest deviation values are recorded for Zhejiang Shibao (01057) at 136.00%, Junda Co. (02865) at 40.42%, and Nanjing Panda Electronics (00553) at 24.71% [1][2]. - The lowest deviation values are seen in Northeast Electric (00042) at -35.46%, GAC Group (02238) at -26.23%, and Nanhua Futures (02691) at -17.44% [1][3]. Top and Bottom AH Shares - The top ten AH shares by premium rate include companies like Sinopec Oilfield Service (01033) with a premium rate of 271.43% and Fudan Zhangjiang (01349) at 250.53% [1]. - The bottom ten AH shares by premium rate include Weichai Power (02338) at 9.88% and WuXi AppTec (02359) at 10.47% [1].

Market Overview - The Hong Kong stock market opened slightly higher on December 24, with the Hang Seng Index rising 0.02% to 25,780.09 points, the Hang Seng Tech Index up 0.07% to 5,492.83 points, the National Enterprises Index increasing by 0.09% to 8,922.07 points, and the Red Chip Index gaining 0.19% to 4,075.35 points [1] Company News - Pacific Basin Shipping (02343.HK) plans to acquire four newly built small handy bulk carriers for USD 119 million [2] - Xinyi Energy (03868.HK) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for HKD 62 million [3] - Tianjin Port Development (03382.HK) proposes to sell 60% equity of China Railway Storage and Transportation for HKD 22.52 million, primarily engaged in coal sales [4] - Shandong Xinhua Pharmaceutical (00719.HK) has received a drug registration certificate for its Oseltamivir phosphate dry suspension [5] - Yiyuan Yuan (08223.HK) has entered into a strategic cooperation framework agreement with Pengfeng Technology to explore digital transformation opportunities in the traditional Chinese medicine industry [5] - Yihua Tong (02402.HK) completed a placement of 8.88 million shares, raising HKD 198 million, primarily for repaying bank loans [7] - Runge Interactive (02422.HK) plans to place up to 160 million shares at a discount of approximately 19.44%, raising about HKD 68.6 million [8] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million at prices between HKD 602.5 and HKD 613.5 [9] - Kuaishou-W (01024.HK) repurchased 2.7176 million shares for HKD 174 million at prices between HKD 63.7 and HKD 64.65 [10] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 147 million at prices between HKD 39.1 and HKD 39.28 [11] - COSCO Shipping Holdings (01919.HK) repurchased approximately HKD 65.48 million worth of shares, totaling 4.7215 million shares at prices between HKD 13.75 and HKD 13.93 [12] - Huaxin Cement (06655.HK) shareholder Huaxin Group plans to increase its holdings in the company's A-shares by HKD 200 million to HKD 400 million [13] Institutional Insights - Dongwu Securities suggests that while there may be short-term opportunities in the Hong Kong market, it is advisable to maintain a cautious stance. The current position is seen as attractive for medium to long-term allocation, with potential for a "Christmas rally" in US tech stocks that could resonate with Hong Kong tech stocks, although there are concerns about stock unlocks affecting the market [14] - Founder Securities highlights strong demand for energy storage, benefiting both power batteries and energy storage batteries, with expected growth rates of over 15% and 40% respectively by 2026. The lithium market is also expected to see a gradual recovery in supply-demand dynamics, with prices likely to rise [14] - CICC forecasts that global tungsten production will increase from 82,800 tons in 2025 to 89,900 tons by 2028, while demand will rise from 102,100 tons to 110,000 tons, indicating a persistent supply-demand gap. The demand for tungsten-based new materials is expected to grow due to advancements in manufacturing and new applications [15]

Company News - Pacific Shipping (02343.HK) plans to acquire four newly built small handy bulk carriers for USD 119 million [2] - Xinyi Energy (03868.HK) intends to acquire 100% equity of Jinzhai Xinyi Wind Power for HKD 62 million [2] - Tianjin Port Development (03382.HK) proposes to sell 60% equity of China Railway Storage and Transportation for HKD 22.5243 million, primarily engaged in coal sales [2] - Valiant Bio-B (09887.HK) announced the successful administration of LBL-024, a PD-L1/4-1BB bispecific antibody, to the first patient in the Phase Ib/II clinical trial for platinum-resistant ovarian cancer [2] - Shandong Xinhua Pharmaceutical (00719.HK) has received a drug registration certificate for its Oseltamivir phosphate dry suspension [2] - Ziyuan Yuan (08223.HK) signed a strategic cooperation framework agreement with Pengfeng Technology to explore digital transformation and asset value enhancement in the traditional Chinese medicine industry [2] - Jiaxing Gas (09908) terminated its agreement with concerted action persons [2] Financing and Buyback Activities - Yihua Tong (02402.HK) completed a placement of 8.88 million shares, raising HKD 198 million, primarily for repaying bank loans [2] - Rungao Interactive (02422.HK) plans to place up to 160 million shares at a discount of approximately 19.44%, aiming to raise about HKD 68.6 million [2] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with prices ranging from HKD 602.5 to 613.5 [3] - Kuaishou-W (01024.HK) repurchased 2.7176 million shares for HKD 174 million, with prices between HKD 63.7 and 64.65 [3] - Xiaomi Group-W (01810.HK) repurchased 3.75 million shares for HKD 147 million, with prices from HKD 39.1 to 39.28 [4] - COSCO Shipping Holdings (01919) announced a repurchase of 4.7215 million shares for approximately HKD 65.4829 million [4] - Huaxin Cement (06655.HK) major shareholder Huaxin Group plans to increase its holdings in the company's A-shares by HKD 200 million to 400 million [4]

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Suspension from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Group 1 - The company announced the approval of Oseltamivir Phosphate Suspension, which is a key product in its portfolio [1] - The registration certificate signifies compliance with national drug regulations, enhancing the company's market position [1] - This approval may lead to increased sales and market share in the antiviral medication segment [1]

Core Viewpoint - Xinhua Pharmaceutical has received the drug registration certificate for Oseltamivir Phosphate Dry Suspension from the National Medical Products Administration, indicating a significant advancement in its product offerings for influenza treatment and prevention [1] Group 1: Product Approval - The drug is approved for the treatment of influenza A and B in patients aged 2 weeks and older [1] - It can also be used for the prevention of influenza A and B in individuals aged 1 year and above [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Oseltamivir Phosphate Oral Suspension, which is indicated for the treatment of influenza A and B in patients aged 2 weeks and older [1] Group 1 - The product is effective in treating both influenza A and B, although clinical application data for influenza B is limited [1] - Patients are advised to use the product within 48 hours of the onset of symptoms [1] - The product can also be used for the prevention of influenza A and B in individuals aged 1 year and older [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Oseltamivir Phosphate Dry Suspension, which is indicated for the treatment of influenza A and B in patients aged 2 weeks and older [1] Group 1 - The product is effective for treating both influenza A and B, although clinical data for influenza B is limited [1] - Patients are advised to use the product within 48 hours of the onset of symptoms [1] - The product can also be used for the prevention of influenza A and B in individuals aged 1 year and older [1]

格隆汇12月23日丨新华制药(000756.SZ)公布，收到国家药品监督管理局核准签发的磷酸奥司他韦干混 悬剂《药品注册证书》。本品用于2周龄及以上年龄患者的甲型和乙型流感治疗（磷酸奥司他韦能够有 效治疗甲型和乙型流感，但是乙型流感的临床应用数据尚不多）。患者应在首次出现症状48小时以内使 用。本品也可用于1岁及1岁以上人群的甲型和乙型流感的预防。 ...

山东新华制药股份(00719.HK)公布，近日，公司收到国家药品监督管理局核准签发的磷酸奥司他韦干混 悬剂《药品注册证书》。 本文源自：金融界AI电报 ...

证券代码：000756 证券简称：新华制药 公告编号：2025-70 山东新华制药股份有限公司 关于获得磷酸奥司他韦干混悬剂药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，山东新华制药股份有限公司（以下简称"新华制药"或"公司"）收到国家药品 监督管理局核准签发的磷酸奥司他韦干混悬剂（以下简称"本品"）《药品注册证书》。现将 相关情况公告如下： 注册分类：化学药品3类 申请人：山东新华制药股份有限公司 申请事项：药品注册（境内生产） 受理号：CYHS2401142 药品批准文号：国药准字H20256303； 证书编号：2025S03820； 一、基本情况 药品名称：磷酸奥司他韦干混悬剂 剂型：口服混悬剂 规格：0.36g（按C16H28N2O4计） 药品分类：非处方药 三、对上市公司的影响及风险提示 新华制药申报的磷酸奥司他韦干混悬剂于2025年12月获得药品注册证书，丰富了公司 抗病毒药物产品线，有利于提升公司综合竞争力。 因药品销售业务易受到国内医药行业政策变动、招标采购、市场环境变化等因素影响， 存在不确定性，敬请广大投资者理性 ...